Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 18/20 | 0.81 |
| ▸ | SLC6A2 | P23975 | 13/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11801805 | 0.95 | SLC6A4 (0.83) | SLC6A4SLC6A2SLC6A3SIGMAR1CYP1A2 | |
| SCHEMBL5444533 | 0.89 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3CYP1A2CYP2D6 | |
| SCHEMBL12806751 | 0.84 | SLC6A4 (0.64) | SLC6A4SLC6A2SLC6A3CYP1A2CYP2D6 | |
| SCHEMBL12806778 | 0.82 | SLC6A4 (0.66) | SLC6A4SLC6A2SLC6A3CYP1A2CYP2D6 | |
| SCHEMBL20804351 | 0.81 | CCR3 (0.59) | SLC6A4SIGMAR1MEN1KMT2A | |
| SCHEMBL26358361 | 0.80 | SLC6A4 (0.52) | SLC6A4SLC6A2SLC6A3SIGMAR1CYP1A2 | |
| SCHEMBL6171525 | 0.80 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3CYP1A2CYP2D6 | |
| SCHEMBL5915354 | 0.79 | SLC6A4 (0.62) | SLC6A4SLC6A2SLC6A3SIGMAR1CYP2D6 | |
| SCHEMBL9816200 | 0.78 | SLC6A4 (0.69) | SLC6A4SLC6A2SLC6A3CYP1A2CYP2D6 | |
| SCHEMBL10413788 | 0.78 | SLC6A4 (0.69) | SLC6A4SLC6A2SLC6A3CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230302030-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS INHIBITORS OF RAN GTPase | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CA) | 2023-09-28 | — | — | US | disclosed |
| US-20200246365-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS INHIBITORS OF RAN GTPASE | CENTRE HOSPITALIER DE L'UNIVERSITÉ DE MONTRÉAL (CA) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200246365-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS INHIBITORS OF RAN GTPASE | RAN, RANBP1, GDI2 | SLC6A4 2520/4885SLC6A2 2795/4885SLC6A3 2755/4885 |
| US-20230302030-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS INHIBITORS OF RAN GTPase | RAN, RANBP1, GDI2 | SLC6A4 2520/4885SLC6A2 2795/4885SLC6A3 2755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.